Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach
Authors:
Open Access
- 7 March 2023
- journal article
- review article
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 23 (4) , 121-130
Abstract
Purpose of Review: Genetic variants in GBA1 and LRRK2 genes are the commonest genetic risk factor for Parkinson disease (PD); however, the preclinical profile of GBA1 and LRRK2 variant carriers who will develop PD is unclear. This review aims to highlight the more sensitive markers that can stratify PD risk in non-manifesting GBA1 and LRRK2 variant carriers. Recent Findings: Several case–control and a few longitudinal studies evaluated clinical, biochemical, and neuroimaging markers within cohorts of non-manifesting carriers of GBA1 and LRRK2 variants. Summary: Despite similar levels of penetrance of PD in GBA1 and LRRK2 variant carriers (10–30%), these individuals have distinct preclinical profiles. GBA1 variant carriers at higher risk of PD can present with prodromal symptoms suggestive of PD (hyposmia), display increased α-synuclein levels in peripheral blood mononuclear cells, and show dopamine transporter abnormalities. LRRK2 variant carriers at higher risk of PD might show subtle motor abnormalities, but no prodromal symptoms, higher exposure to some environmental factors (non-steroid anti-inflammatory drugs), and peripheral inflammatory profile. This information will help clinicians tailor appropriate screening tests and counseling and facilitate researchers in the development of predictive markers, disease-modifying treatments, and selection of healthy individuals who might benefit from preventive interventions.Keywords
Funding Information
- Aligning Science Across Parkinson's (ASAP-000420)
- EU Joint Programme – Neurodegenerative Disease Research (MR/T046007/1)
- Università degli Studi di Pavia
This publication has 85 references indexed in Scilit:
- Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson DiseaseJAMA Neurology, 2015
- Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutationsMovement Disorders, 2013
- Hyposmia and cognitive impairment in Gaucher disease patients and carriersMovement Disorders, 2012
- Gait alterations in healthy carriers of the LRRK2 G2019S mutationAnnals of Neurology, 2011
- Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2Movement Disorders, 2009
- Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's diseaseBrain, 2009
- Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyThe Lancet Neurology, 2008
- Nonsteroidal anti-inflammatory drugs may protect against Parkinson diseaseNeurology, 2007
- Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi JewsNew England Journal of Medicine, 2004
- Sex differences in uric acid metabolism in adults: Evidence for a lack of influence of estradiol-17β (E2) on the renal handling of urateMetabolism, 1986